Design and development of donepezil hydrochloride loaded nanostructured lipid carriers for efficient management of Alzheimer’s disease

References

• Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111–128. doi:10.31887/DCNS.2009.11.2/cqiu.
   PubMedGoogle Scholar
• Uwishema O, Mahmoud A, Sun J, et al. Is Alzheimer's disease an infectious neurological disease? A review of the literature. Brain Behav. 2022;12:e2728.
   PubMed Web of Science ®Google Scholar
• Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ. 2019;367:l6217. doi:10.1136/bmj.l6217.
   PubMed Web of Science ®Google Scholar
• Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59–70. doi:10.1111/ene.13439.
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Ocic G. Clinical manifestations of Alzheimer’s disease. Psihijatrija Danas. 1994;26:173–178.
   Google Scholar
• Erdő F, Bors LA, Farkas D, et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155–170. doi:10.1016/j.brainresbull.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184–1189. doi:10.1016/s1359-6446(02)02529-1.
   PubMed Web of Science ®Google Scholar
• Sonvico F, Clementino A, Buttini F, et al. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics. 2018;10(1):34. doi:10.3390/pharmaceutics10010034.
   PubMed Web of Science ®Google Scholar
• Banks WA. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol. 1999;5(6):538–555. doi:10.3109/13550289909021284.
   PubMed Web of Science ®Google Scholar
• Cunha S, Forbes B, Sousa Lobo JM, et al. Improving drug delivery for Alzheimer’s disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. Int J Nanomedicine. 2021;16:4373–4390. doi:10.2147/IJN.S305851.
   PubMed Web of Science ®Google Scholar
• Gomaa E, Fathi HA, Eissa NG, et al. Methods for preparation of nanostructured lipid carriers. Methods. 2022;199:3–8. doi:10.1016/j.ymeth.2021.05.003.
   PubMed Web of Science ®Google Scholar
• Javidi S, Razavi BM, Hosseinzadeh H. A review of neuropharmacology effects of Nigella sativa and its main component, thymoquinone. Phytother Res. 2016;30(8):1219–1229. doi:10.1002/ptr.5634.
   PubMed Web of Science ®Google Scholar
• Hosseini A, Baradaran Rahimi V, Rakhshandeh H, et al. Nigella sativa oil reduces LPS-induced microglial inflammation: an evaluation on M1/M2 balance. Evid-Based Complement Altern Med. 2022;2022:1–11. doi:10.1155/2022/5639226.
   Web of Science ®Google Scholar
• Souvik C, Sujit D, Koushiknarayan S. Nose-to-brain drug delivery: an update to the alternative path to successful targeted anti-migraine drugs. Int J Appl Pharm. 2021;13(2):67–75.
   PubMedGoogle Scholar
• Sahoo L. Nanostructured lipid carrier (NLC)-a promising drug delivery for transdermal application. J Pharm Sci Res. 2020;12(4):475–487.
   Google Scholar
• Beloqui A, Solinís MÁ, Rodríguez-Gascón A, et al. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–161. doi:10.1016/j.nano.2015.09.004.
   PubMed Web of Science ®Google Scholar
• Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598–613. doi:10.1016/j.biopha.2018.04.055.
   PubMed Web of Science ®Google Scholar
• Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):27–40. doi:10.3109/21691401.2014.909822.
   PubMed Web of Science ®Google Scholar
• Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Delivery Sci Technol. 2019;51:255–267. doi:10.1016/j.jddst.2019.02.017.
   Web of Science ®Google Scholar
• Sharma A, Baldi A. Nanostructured lipid carriers: a review. J Dev Drugs. 2018;7(2):1–12.
   Google Scholar
• El-Helw A-R, Fahmy U. Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers. Int J Nanomedicine. 2015;10:5797–5804. doi:10.2147/IJN.S91556.
   PubMed Web of Science ®Google Scholar
• Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61(5):375–386.
   PubMed Web of Science ®Google Scholar
• Zhang K, Lv S, Li X, et al. Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin. Int J Nanomedicine. 2013;8:3227–3239. doi:10.2147/IJN.S45031.
   PubMed Web of Science ®Google Scholar
• Jadhav SM, Mishra SK. Spray dried mucoadhesive microparticles of donepezil with chitosan and carbopol in Alzheimer’s disease. Int J Pharm Invest. 2022;12(2):205–210. doi:10.5530/ijpi.2022.2.36.
   Web of Science ®Google Scholar
• Devkar TB, Tekade AR, Khandelwal KR. Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron hcl using delonix regia gum as a natural mucoadhesive polymer. Colloids Surf B Biointerfaces. 2014;122:143–150. doi:10.1016/j.colsurfb.2014.06.037.
   PubMed Web of Science ®Google Scholar
• Sahak MK, Kabir N, Abbas G, et al. The role of Nigella sativa and its active constituents in learning and memory. Evid-Based Complement Altern Med. 2016;2016:1–6. doi:10.1155/2016/6075679.
   Web of Science ®Google Scholar
• Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)–based gel of valdecoxib. Drug Dev Ind Pharm. 2006;32(8):911–918. doi:10.1080/03639040600814676.
   PubMed Web of Science ®Google Scholar
• Washington N, Steele RJC, Jackson SJ, et al. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm. 2000;198(2):139–146. doi:10.1016/s0378-5173(99)00442-1.
   PubMedGoogle Scholar
• Sun M, Nie S, Pan X, et al. Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces. 2014;113:15–24. doi:10.1016/j.colsurfb.2013.08.032.
   PubMed Web of Science ®Google Scholar
• Youssef NA, Kassem AA, Farid RM, et al. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: preparation, characterization and in vivo evaluation. Int J Pharm. 2018;548(1):609–624. doi:10.1016/j.ijpharm.2018.07.014.
   PubMedGoogle Scholar
• Patil RP, Pawara DD, Gudewar CS, et al. Nanostructured cubosomes in an in situ nasal gel system: an alternative approach for the controlled delivery of donepezil hcl to brain. J Liposome Res. 2019;29(3):264–273. doi:10.1080/08982104.2018.1552703.
   PubMed Web of Science ®Google Scholar
• Abourehab MA, Khames A, Genedy S, et al. Sesame oil-based nanostructured lipid carriers of nicergoline, intranasal delivery system for brain targeting of synergistic cerebrovascular protection. Pharmaceutics. 2021;13(4):581. doi:10.3390/pharmaceutics13040581.
   PubMed Web of Science ®Google Scholar
• Kumari PV, Srinivasa RY. Formulation and evaluation of orodispersible tablets of donepezil hydrochloride. Int J Curr Pharm Res. 2020;12(4):45–51.
   Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379(1):146–157. doi:10.1016/j.ijpharm.2009.06.019.
   PubMed Web of Science ®Google Scholar
• Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCS) for nasal administration: design, characterization, and in vivo study. Drug Deliv. 2016;23(4):1326–1334. doi:10.3109/10717544.2014.975382.
   PubMed Web of Science ®Google Scholar
• Jazuli I, Annu, Nabi B, et al. Optimization of nanostructured lipid carriers of lurasidone hydrochloride using Box-Behnken design for brain targeting: in vitro and in vivo studies. J Pharm Sci. 2019;108(9):3082–3090. doi:10.1016/j.xphs.2019.05.001.
   PubMed Web of Science ®Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11(1):1–18. doi:10.1016/s0928-0987(00)00087-7.
   PubMed Web of Science ®Google Scholar
• Zhang Q-Z, Zha L-S, Zhang Y, et al. The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J Drug Target. 2006;14(5):281–290. doi:10.1080/10611860600721051.
   PubMed Web of Science ®Google Scholar
• Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res. 2010;27(9):1759–1771. doi:10.1007/s11095-010-0141-7.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54 Suppl 1:S131–S155. doi:10.1016/s0169-409x(02)00118-7.
   PubMed Web of Science ®Google Scholar
• Wavikar P, Pai R, Vavia P. Nose to brain delivery of rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics. J Pharm Sci. 2017;106(12):3613–3622. doi:10.1016/j.xphs.2017.08.024.
   PubMed Web of Science ®Google Scholar
• Amin M. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 2013;7:DTI.S12519. doi:10.4137/DTI.S12519.
   Google Scholar
• Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288–311. doi:10.18433/j3nc79.
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm Res. 2005;22(1):86–93. doi:10.1007/s11095-004-9013-3.
   PubMed Web of Science ®Google Scholar
• Westin U, Piras E, Jansson B, et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci. 2005;24(5):565–573. doi:10.1016/j.ejps.2005.01.009.
   PubMed Web of Science ®Google Scholar
• Ambruosi A, Yamamoto H, Kreuter J. Body distribution of polysorbate‐80 and doxorubicin-loaded [14c]poly(butyl cyanoacrylate) nanoparticles after I.V. administration in rats. J Drug Targeting. 2005;13(10):535–542. doi:10.1080/10611860500411043.
   PubMed Web of Science ®Google Scholar
• Esposito E, Ravani L, Drechsler M, et al. Cannabinoid antagonist in nanostructured lipid carriers (NLCS): design, characterization and in vivo study. Mater Sci Eng C Mater Biol Appl. 2015;48:328–336. doi:10.1016/j.msec.2014.12.012.
   PubMed Web of Science ®Google Scholar
• Rajput A, Butani S. Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil. Asian J Pharmaceutics. 2018;12(4):293–302.
   Web of Science ®Google Scholar
• Yasir M, Zafar A, Noorulla KM, et al. Nose to brain delivery of donepezil through surface modified NLCS: formulation development, optimization, and brain targeting study. J Drug Delivery Sci Technol. 2022;75:103631. doi:10.1016/j.jddst.2022.103631.
   Web of Science ®Google Scholar
• Amin S, Mir SR, Kohli K, et al. A study of the chemical composition of black cumin oil and its effect on penetration enhancement from transdermal formulations. Nat Prod Res. 2010;24(12):1151–1157. doi:10.1080/14786410902940909.
   PubMed Web of Science ®Google Scholar